HI observations of nearby galaxies I. The first list of the Karachentsev catalog

We present HI observations of the galaxies in the first list of the Karachentsev catalog of previously unknown nearby dwarf galaxies (Karachentseva & Karachentsev 1998). This survey covers all known nearby galaxy groups within the Local Volume (i.e. within 10 Mpc) and their environment, that is about 25% of the total sky. A total of 257 galaxies have been observed with a detection rate of 60%. We searched a frequency band corresponding to heliocentric radial velocities from -470 km/s to about +4000 km/s. Non-detections are either due to limited coverage in radial velocity, confusion with Local HI (mainly in the velocity range -140 km/s to +20 km/s, or lack of sensitivity for very weak emission. 25% of the detected galaxies are located within the Local Volume. Those galaxies are dwarf galaxies judged by their optical linear diameter (1.4 +/- 0.2 kpc on the average), their mean total HI mass (4.6 E7 solar masses), and their observed linewidths (39 km/s).Comment: 22 pages, 9 ps figures, A&AS, in pres

Pengobatan Artesunat pada Penderita Malaria Falsiparum tanpa Komplikasi di Daerah Resisten Multidrug

A treatment trial of artesunate for uncomplicated falciparum malaria cases was conducted at ITCI Hospital, Balikpapan, East Kalimantan, Indonesia, in November 1992 - Januari 1993. The objectives of this study were to assess the efficacy and safety of artesunate. Thirty eight falcipamm malaria patients who had been selected according to criteria for the in vivo sensitivity test were treated orally with 100 mg artesunate 12 hourly on DO and followed 50 mg 12 hourly on Dl-4. All patients were hospitalized until declared cured clinically and parasitologicalty. The most prevalent clinical symptoms of these malaria patients were fever (84,2%), headache (81,6%), nausea (73,7%) and splenomegaly (71,0%o). The cure rates of artesunate were 100% (38/38 and 28/28) on D7 and D14, but on D21 and D28 there were 88,2% (15/17) and 75% (6/8) because of the presence of late Rl cases. The mean fever clearance time (FCT) and parasite clearance time (PCT) were as follows 15,1 1,8 h and 32,1 3,0 h (D7), 14,1 2,2 h and 33,3 3,8 h (D14), 15,7 3,0 h and 37,6 5,6 h (D21), 14,0 4,6 h and 32,0 5,9 h (D28) respectively. No side effect was found clinically and on laboratory examinations. Artesunate is effective and safe for treatment of uncomplicated falciparum malaria until D14 in a multidrug resistant area. A sequential combination of artesunate and other antimalarial drugs should be studied to achieve a radical cure

The magnetic field of the proto-planetary nebula candidate IRAS 19296+2227

Context: Magnetic fields are thought to be one of the possible mechanisms responsible for shaping the generally spherical outflow of evolved stars into often aspherical planetary nebulae. However, direct measurements of magnetic fields during the transition to the planetary nebula phase are rare. Aims: The aim of this project is to expand the number of magnetic field measurements of stars in the (proto-)planetary nebula phase and find if the magnetic field strength is sufficient to affect the stellar outflow. Methods: We used Very Long Baseline Array observations to measure the circular polarization due to the Zeeman splitting of 22 GHz water masers in the envelope of the proto-planetary nebula candidate star IRAS 19296+2227 and the planetary nebula K3-35. Results: A strong magnetic field of B||=-135+-28 is detected in the water maser region of the proto-planetary nebula candidate IRAS 19296+2227. The water masers of K3-35 are too weak to detect circular polarization although we do present the measurements of weak linear polarization in those masers. Conclusions: The field measured in the masers of IRAS 19296+2227 is dynamically important and, if it is representative of the large scale field, is an important factor in driving the stellar mass loss and shaping the stellar outflow.Comment: 5 pages, 3 figures; A&A accepte

Pengobatan Malaria Falsiparum tanpa Komplikasi dengan Halofantrin di Daerah Resisten Klorokuin

Treatment of uncomplicated falciparum malaria with halofantrine was carried out at ITCI Hospital, Balikpapan, East Kalimantan, Indonesia in 1990/1991. This study was conducted to assess the efficacy and safety of halofantrine. Eighty out of 96 malaria falciparum patients who had been selected according to WHO criteria for the in-vivo sensitivity test were treated with 500 mg halofantrine 6 hourly for three doses orally. The other 16 patients were treated with mefloquine 750 mg single dose orally as a control group. All patients were hospitalized for 3-5 days and followed up on day 7, 14, 21 and 28. The cure rate of halofantrine was 98.4% (62/63) and relapse rate was 1.6% (1/63) as a late RI. The mean fever clearance time (FCT) and parasite clearance time (PCT) were 22.4 ± 2.7 h and 58.3 ± 5.2 h respectively. Tlte FCT was significantly different compared to that of mefloquine (9.3 ± 2.4 h). Some haematological abnormalities appeared to be associated with malaria but no biochemical abnormalities were found. Mild diarrhoea (11.5%), nausea (6.4%), palpitation (2.6%) and dizziness (1.3%) were observed as side effects of halofantrine but disappeared without treatment.This study showed that halofantrine is effective and safe for the treatment of uncomplicated falciparum malaria in a chloroquine resistant area

The vacuum bubbles in de Sitter background and black hole pair creation

We study the possible types of the nucleation of vacuum bubbles. We classify vacuum bubbles in de Sitter background and present some numerical solutions. The thin-wall approximation is employed to obtain the nucleation rate and the radius of vacuum bubbles. With careful analysis we confirm that Parke's formula is also applicable to the large true vacuum bubbles. The nucleation of the false vacuum bubble in de Sitter background is also evaluated. The tunneling process in the potential with degenerate vacua is analyzed as the limiting cases of the large true vacuum bubble and false vacuum bubble. Next, we consider the pair creation of black holes in the background of bubble solutions. We obtain static bubble wall solutions of junction equation with black hole pair. The masses of created black holes are uniquely determined by the cosmological constant and surface tension on the wall. Finally, we obtain the rate of pair creation of black holes.Comment: 3 figures, minor including errors and typos corrected, and refs. adde

Pengobatan Penderita Malaria Falsiparum tanpa Komplikasi dengan Meflokuin di Daerah Resisten Klorokuin

Treatment with mefloquine of uncomplicated falciparum malaria patients was undertaken in ITCI Hospital, Balikpapan, East Kalimantan, Indonesia in 1991. This study was conducted to assess the efficacy and safety of mefloquine, and to assess in vitro sensitivity of P. falciparum to other antimalarials currently in use. A total of 16 falciparum malaria patients who had been selected according to WHO criteria for the drug sensitivity test were treated with 750 mg mefloquine single dose orally. All patients were hospitalized for 3-5 days and followed up on day 7, 14, 21 and 28. Clinical and parasitological examinations were carried out during the study, haematological and biochemical examinations were also performed before drug administration and when the patient was discharged from the hospital. The main presenting symptoms were chills, headache and fever. Cure rate was 100% with the mean fever clearance time and parasite clearance time was 9.3 ±_ 2.4 hours and 47.1 +_ 3.7 hours respectively. No significant drug-related changes were noted in hematological or biochemical parameters. Only nausea was observed as a side effect of mefloquine which was mild and disappeared without treatment. ITCI Hospital area is a highly chloroquine resistant area (90,9%) and also as a multidrug resistant area (50%). This study shows that mefloquine is effective and safe for the treatment of uncomplicated falcipamm malaria resistant to chloroquine as well as for multidrug resistant cases

Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response

Given the high costs of conducting a drug-response trial, researchers are now aiming to use retrospective analyses to conduct genome-wide association studies (GWAS) to identify underlying genetic contributions to drug-response variation. To prevent confounding results from a GWAS to investigate drug response, it is necessary to account for concomitant medications, defined as any medication taken concurrently with the primary medication being investigated. We use data from the Action to Control Cardiovascular Disease (ACCORD) trial in order to implement a novel scoring procedure for incorporating concomitant medication information into a linear regression model in preparation for GWAS. In order to accomplish this, two primary medications were selected: thiazolidinediones and metformin because of the wide-spread use of these medications and large sample sizes available within the ACCORD trial. A third medication, fenofibrate, along with a known confounding medication, statin, were chosen as a proof-of-principle for the scoring procedure. Previous studies have identified SNP rs7412 as being associated with statin response. Here we hypothesize that including the score for statin as a covariate in the GWAS model will correct for confounding of statin and yield a change in association at rs7412. The response of the confounded signal was successfully diminished from p = 3.19 × 10−7 to p = 1.76 × 10−5, by accounting for statin using the scoring procedure presented here. This approach provides the ability for researchers to account for concomitant medications in complex trial designs where monotherapy treatment regimens are not available

Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial

Background Individuals with type 2 diabetes are at an increased risk of cardiovascular disease. Alterations in circulating lipid levels, total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) are heritable risk factors for cardiovascular disease. Here we conduct a genome-wide association study (GWAS) of common and rare variants to investigate associations with baseline lipid levels in 7,844 individuals with type 2 diabetes from the ACCORD clinical trial. Methods DNA extracted from stored blood samples from ACCORD participants were genotyped using the Affymetrix Axiom Biobank 1 Genotyping Array. After quality control and genotype imputation, association of common genetic variants (CV), defined as minor allele frequency (MAF) ≥ 3%, with baseline levels of TC, LDL, HDL, and TG was tested using a linear model. Rare variant (RV) associations (MAF < 3%) were conducted using a suite of methods that collapse multiple RV within individual genes. Results Many statistically significant CV ( p  < 1 × 10 −8 ) replicate findings in large meta-analyses in non-diabetic subjects. RV analyses also confirmed findings in other studies, whereas significant RV associations with CNOT2 , HPN-AS1 , and SIRPD appear to be novel ( q  < 0.1). Discussion Here we present findings for the largest GWAS of lipid levels in people with type 2 diabetes to date. We identified 17 statistically significant ( p  < 1 × 10 −8 ) associations of CV with lipid levels in 11 genes or chromosomal regions, all of which were previously identified in meta-analyses of mostly non-diabetic cohorts. We also identified 13 associations in 11 genes based on RV, several of which represent novel findings

Mechanisms of Hemolysis-Associated Platelet Activation

Background Intravascular hemolysis occurs after blood transfusion, in hemolytic anemias, and in other conditions, and is associated with hypercoagulable states. Hemolysis has been shown to potently activate platelets in vitro and in vivo, and several mechanisms have been suggested to account for this, including: (i) direct activation by hemoglobin (Hb); (ii) increase in reactive oxygen species (ROS); (iii) scavenging of nitric oxide (NO) by released Hb; and (iv) release of intraerythrocytic ADP. Objective To elucidate the mechanism of hemolysis-mediated platelet activation. Methods We used flow cytometry to detect PAC-1 binding to activated platelets for in vitro experiments, and a Siemens\u27 Advia 120 hematology system to assess platelet aggregation by using platelet counts from in vivo experiments in a rodent model. Results We found that Hb did not directly activate platelets. However, ADP bound to Hb could cause platelet activation. Furthermore, platelet activation caused by shearing of red blood cells (RBCs) was reduced in the presence of apyrase, which metabolizes ADP to AMP. The use of ROS scavengers did not affect platelet activation. We also found that cell-free Hb enhanced platelet activation by abrogating the inhibitory effect of NO on platelet activation. In vivo infusions of ADP and purified (ADP-free) Hb, as well as hemolysate, resulted in platelet aggregation, as shown by decreased platelet counts. Conclusion Two primary mechanisms account for RBC hemolysis-associated platelet activation: ADP release, which activates platelets; and cell-free Hb release, which enhances platelet activation by lowering NO bioavailability